**PrecISE, the Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network**, is a research study to understand how to treat different types of severe asthma. We are looking for people who have asthma attacks or frequent asthma symptoms. Everyone in the study will receive one or more study medicines for their severe asthma. This study is sponsored by the U.S. National Heart, Lung, and Blood Institute (NHLBI). For more information about PrecISE, call us at 615-421-8328 or email us at precisestudy@vumc.org.

The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.

PrecISE is a clinical study sponsored by the U.S. National Heart, Lung, and Blood Institute (NHLBI) to investigate several treatments for severe asthma. PrecISE will enroll 800 adults and teenagers (ages 12 years and older) with severe asthma who have symptoms that are not well-controlled on high dose of inhaled corticosteroids including those who have frequent asthma attacks. Each person who agrees to enroll in the PrecISE study will receive several treatments for research purposes based on their type of severe asthma.

The goal of PrecISE is to understand how to treat different types of severe asthma, by using precision medicine. Precision medicine is an approach that targets treatments to defined subgroups of patients who share similar characteristics, for example, patients with a certain genetic variation or patients with high number of blood eosinophils.

Researchers from over 30 locations across the US, as well as sites in Canada and the United Kingdom, are involved in PrecISE.